Gal Ben-Arie

Dr. Gal Ben-Arie

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DMDan Z. Milikovsky
Dan Z. Milikovsky
JOJonathan Ofer
Jonathan Ofer
VSVladimir V. Senatorov
Vladimir V. Senatorov
AFAaron R. Friedman
Aaron R. Friedman
OPOfer Prager
Ofer Prager
AFAlon Friedman
Alon Friedman
Transient EEG slowing events are shared by patients and models of Alzheimer’s and epilepsy and are associated with blood-brain barrier dysfunction.

Verified
Journal Article
Open access
PDF file
NMNataly Makarenkov
Nataly Makarenkov
UYUri Yoel
Uri Yoel
YHYulia Haim
Yulia Haim
YPYair Pincu
Yair Pincu
Nikhil Suresh BhandarkarNikhil Suresh Bhandarkar
Nikhil Suresh Bhandarkar
IVIsana Veksler-Lublinsky
Isana Veksler-Lublinsky
Circulating miRNAs are increasingly being considered as biomarkers in various medical contexts, but the value of analyzing isomiRs (isoforms of canonical miRNA sequences) has not frequently been assessed. Here we hypothesize that an in-depth analysis of the full circulating miRNA landscape could identify specific isomiRs that are stronger biomarkers, compared to their corresponding miRNA, for identifying increased CV risk in patients with non-alcoholic fatty liver disease (NAFLD)—a clinical unmet need. Plasma miRNAs were sequenced with next-generation sequencing (NGS). Liver fat content was measured with magnetic-resonance spectrometry (MRS); CV risk was determined, beyond using traditional biomarkers, by a CT-based measurement of coronary artery calcium (CAC) score and the calculation of a CAC score-based CV-risk percentile (CAC-CV%). This pilot study included n = 13 patients, age > 45 years, with an MRS-measured liver fat content of ≥5% (wt/wt), and free of overt CVD. NGS identified 1103 miRNAs and 404,022 different isomiRs, of which 280 (25%) and 1418 (0.35%), respectively, passed an abundance threshold. Eighteen (sixteen/two) circulating miRNAs correlated positively/negatively, respectively, with CAC-CV%, nine of which also significantly discriminated between high/low CV risk through ROC-AUC analysis. IsomiR-ome analyses uncovered 67 isomiRs highly correlated (R ≥ 0.55) with CAC-CV%. Specific isomiRs of miRNAs 101-3p, 144-3p, 421, and 484 exhibited stronger associations with CAC-CV% compared to their corresponding miRNA. Additionally, while miRNAs 140-3p, 223-3p, 30e-5p, and 342-3p did not correlate with CAC-CV%, specific isomiRs with altered seed sequences exhibited a strong correlation with coronary atherosclerosis burden. Their predicted isomiRs-specific targets were uniquely enriched (compared to their canonical miRNA sequence) in CV Disease (CVD)-related pathways. Two of the isomiRs exhibited discriminative ROC-AUC, and another two showed a correlation with reverse cholesterol transport from cholesterol-loaded macrophages to ApoB-depleted plasma. In summary, we propose a pipeline for exploring circulating isomiR-ome as an approach to uncover novel and strong CVD biomarkers.

28 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SPStephanie Perrino
Stephanie Perrino
UVUdi Vazana
Udi Vazana
OPOfer Prager
Ofer Prager
LSLior Schori
Lior Schori
GBGal Ben-Arie
Gal Ben-Arie
PBPnina Brodt
Pnina Brodt
Background: Glioblastoma multiforme is an aggressive malignancy with a dismal 5-year survival rate of 5–10%. Current therapeutic options are limited, due in part to drug exclusion by the blood–brain barrier (BBB). We have previously shown that high-amplitude repetitive transcranial magnetic stimulation (rTMS) in rats allowed the delivery across the BBB of an IGF signaling inhibitor—IGF-Trap. The objective of this study was to assess the therapeutic effect of IGF-Trap when delivered in conjunction with rTMS on the intracerebral growth of glioma. Results: We found that systemic administration of IGF-Trap without rTMS had a minimal effect on the growth of orthotopically injected glioma cells in rats and mice, compared to control animals injected with vehicle only or treated with sham rTMS. In rats treated with a combination of rTMS and IGF-Trap, we observed a growth retardation of C6 tumors for up to 14 days post-tumor cell injection, although tumors eventually progressed. In mice, tumors were detectable in all control groups by 14–17 days post-injection of glioma GL261 cells and progressed rapidly thereafter. In mice treated with rTMS prior to IGF-Trap administration, tumor growth was inhibited or delayed, although the tumors also eventually progressed. Conclusion: The results showed that rTMS could increase the anti-tumor effect of IGF-Trap during the early phases of tumor growth. Further optimization of the rTMS protocol is required to improve survival outcomes.

2 May 2022 in Pathobiology
Verified
Journal Article
Open access
PDF file
JCJonah M. Cooper
Jonah M. Cooper
BSBenzion Samueli
Benzion Samueli
EMElad Mazor
Elad Mazor
WKWaleed Kian
Waleed Kian
HGHadar Goldvaser
Hadar Goldvaser
GBGal Ben-Arie
Gal Ben-Arie
Introduction: Lobular breast cancer represents 10%–15% of breast cancers in women but is virtually nonexistent in men, related to the typical absence of the anatomic breast lobule structure in male breast tissue. We describe donor-transmitted metastatic lobular carcinoma to a male after kidney transplantation. Determining whether a post-transplant cancer is transplant associated, donor transmitted, or donor derived is significant for treatment, prognosis, and possibly management of other organ recipients. Case Report: A 74-year-old Caucasian male presented to the emergency department with lower abdominal pain and macro-hematuria. Past medical history included two renal transplantations. Computed tomography identified a 4–5-cm space-occupying lesion in the native left kidney. A left native nephrectomy was performed. Histology pathologic examination demonstrated lobular (as opposed to ductal) breast carcinoma. Fluorescent in situ hybridization probes to identify X- and Y-chromosomes showed tumor cells with an XX genotype, whereas the surrounding host cells were of XY genotype. These findings confirmed the female-sex origin (donor) of the tumor within the XY native male (current patient) tissues. Discussion/Conclusion: Due to discordance between the donor and recipient sex, fluorescent in situ hybridization as a molecular technique correctly identified the origin of an individual’s cancer in the post-transplant setting. The metastatic breast cancer behaved more indolently than usually seen. Expanded criteria donors (ECD) are those who cannot donate under standard criteria for organ transplantation; expanded criteria widen the potential organ donor pool at the expense of increased risk for post-transplant complications (e.g., graft failure, the transmission of malignancy). The case provides a potential area of future research into considering allowing ECDs with a distant history of cancer with very low transmission risk when the biochemical environment of the recipient would, in the unlikely event of transmission, induce the tumor to pursue an indolent clinical course.

8 August 2025 in Autism Research
Verified
Journal Article
Open access
GBGal Ben-Arie
Gal Ben-Arie
ISIlan Shelef
Ilan Shelef
GMGal Meiri
Gal Meiri
IMIdan Menashe
Idan Menashe
IDIlan Dinstein
Ilan Dinstein
AAAyelet Arazi
Ayelet Arazi
Benign external hydrocephalus (BEH) is evident in < 0.6% of births. It is defined by abnormally large cerebrospinal fluid (CSF) volumes in the subarachnoid space (SAS) and otherwise normal neuroimaging findings before 2 years of age. BEH has not been associated with specific developmental disorders and is not treated because it usually resolves spontaneously. However, quantitative MRI studies have reported that some toddlers with autism exhibit enlarged extra‐axial CSF (EA‐CSF) volumes. Our objective was to determine whether a subgroup of children with autism exhibits both qualitative BEH and quantitative EA‐CSF volume enlargements. We analyzed clinical brain MRI scans in a retrospective sample of 136 children, 5–99 months old, 83 with autism, who were assessed for BEH by neuroradiologists. EA‐CSF volume and total cerebral volume (TCV) were quantified in T2‐weighted scans by manual labeling. Measures were compared across groups while stratifying participants by age. Neuroradiologists reported BEH findings in 33% of autistic children scanned before the age of 2 years old (i.e., before autism diagnosis). Quantitative MRI analyses demonstrated that autistic children in this age group exhibited significantly larger EA‐CSF volumes relative to controls ( t (49) = 2.89, p = 0.006, Cohen's d = 0.82) with 30% of autistic children and 9.5% of the controls exhibiting EA‐CSF/TCV ratios > 0.14, a previously suggested threshold of potential clinical relevance. EA‐CSF differences were not apparent in older children. The prevalence of BEH associated with quantifiable EA‐CSF enlargements was remarkably high in toddlers who later developed autism, suggesting a specific autism etiology involving early transient CSF circulation problems with potentially long‐lasting neurodevelopmental impact.

31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IGItamar Gothelf
Itamar Gothelf
MEMaor Epstein
Maor Epstein
ASAdi Shiloh
Adi Shiloh
ZLZachary Lebowitz
Zachary Lebowitz
YZYair Zlotnik
Yair Zlotnik
Anat HorevAnat Horev
Anat Horev
Objective: Stent-assisted treatments for intracranial aneurysms, including stent-assisted coiling (SAC) and flow diversion (FD), are associated with an increased thrombotic risk despite dual antiplatelet therapy (DAPT). Recently, intravenous prophylactic protocols incorporating glycoprotein IIb/IIIa antagonists, adapted from cardiology practices, have been introduced. This study evaluates the safety and efficacy of prophylactic low-dose intra-arterial Eptifibatide for cerebral aneurysm management using SAC or FD. Methods: This single-center, single-arm, retrospective study included 99 patients who underwent endovascular treatment with stent-assisted coiling (SAC) or flow diversion (FD) between 2017 and 2023. All patients were initiated on dual antiplatelet therapy (DAPT) 7 days prior to the procedure. Prophylactic intra-arterial Eptifibatide (2–3 mg) was administered intra-procedurally, immediately after stent deployment. Complications were recorded and categorized as periprocedural (occurring during or within 24 h of the procedure) or postprocedural (occurring between 24 and 72 h after the procedure), and included both thrombotic and hemorrhagic events. Results: Among the 99 patients (mean age 57.0 ± 10.8 years), periprocedural complications included three cases of ischemic-related neurological deficits, with no evidence of stent thrombosis or intracranial branch occlusion. All deficits were resolved within 48 h. An additional two patients developed ischemic-related neurological deficits post-procedural. One patient fully recovered following a short rehabilitation period, while the other was left with mild permanent deficits. Overall, any complications following Eptifibatide administration were observed in 5.1% of patients. No hemorrhagic complications were recorded. Conclusions: Prophylactic low-dose intra-arterial Eptifibatide demonstrated a favorable safety profile, potentially reducing thrombotic complications without substantially increasing hemorrhagic risk.